J Int Med Res. 2026 Nov;54(11):3000605261501669. doi: 10.1177/03000605261501669. Epub 2026 Nov 15.
ABSTRACT
ObjectiveTo compare glycemic and metabolic-inflammatory outcomes associated with assignment to a Helicobacter pylori eradication-treatment regimen, metformin, or their combination in adults with type 2 diabetes mellitus and Helicobacter pylori infection.MethodsThis single-center, three-arm, parallel-group, open-label randomized controlled trial enrolled 120 adult outpatients, randomized in a 1:1:1 ratio to a Helicobacter pylori eradication-treatment regimen, metformin, or combined treatment (n = 40 per group). The primary outcome was the change in glycated hemoglobin from baseline to 6 months. Only archived group-by-time cell means, SDs, and sample sizes were available for the present analysis. Longitudinal cell means were analyzed using covariance-adjusted generalized least squares, with sensitivity analyses assuming within-participant correlations of 0.30-0.70.ResultsUnder the summary-data generalized least-squares model with an assumed within-participant correlation of 0.50, glycated hemoglobin showed significant group, time, and group × time effects (P = 1.37e-11, 9.24e-250, and 1.50e-30, respectively). Compared with assignment to the eradication-treatment regimen alone and metformin alone, assignment to combined treatment was associated with greater baseline-to-6-month glycated hemoglobin reductions of 1.76 percentage points (95% confidence interval: 1.43 to 2.09; Holm-adjusted P = 1.78e-25) and 1.77 percentage points (95% confidence interval: 1.41 to 2.13; Holm-adjusted P = 1.49e-22), respectively. Differential longitudinal patterns were also observed for several secondary outcomes. Complication incidence did not differ significantly among groups (P = 0.114).ConclusionsAssignment to the Helicobacter pylori eradication-treatment regimen combined with metformin was associated with greater short-term glycated hemoglobin improvement than assignment to either regimen alone. Because participant-level longitudinal data and post-treatment confirmation of Helicobacter pylori clearance were unavailable, these findings should be interpreted as summary-data associations with treatment-regimen assignment rather than as evidence of an effect mediated by successful eradication.
PMID:43035258 | DOI:10.1177/03000605261501669
